Premium
Can HLA‐DR expression help in the routine diagnosis of malignant melanomas?
Author(s) -
WEST K.P.,
PRIYAKUMAR P.,
JAGJIVAN R.,
COLLOBY P.S.
Publication year - 1989
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1989.tb01796.x
Subject(s) - medicine , pathology , monoclonal antibody , melanoma , staining , nevus , human leukocyte antigen , dermatology , stain , epitope , antibody , antigen , immunology , cancer research
SUMMARY Two monoclonal antibodies, TAL‐1B5 and LN3, directed at epitopes of HLA‐DR were applied to a variety of benign naevi and malignant melanomas. Of the 31 naevi examined, 28 were completely unreactive. Weak staining was confined to a few cells in two intradermal naevi and there was more widespread reactivity in a halo naevus. Seven of the 25 primary cutaneous malignant melanomas were reactive with one or both of the antibodies and this reactivity was more marked in the deeper lesions. These positive cases were not felt to present diagnostic difficulties and it was concluded that TAL‐1B5 and LN3 were not of use in distinguishing between benign and malignant melanocytic proliferations.